OMS906 study drug

DRUG2 trials

Sponsors

Omeros Corporation

Conditions

C3 GlomerulopathyIdiopathic Immune Complex-Mediated GlomerulonephritisParoxysmal Nocturnal Hemoglobinuria

Phase 2

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

RecruitingNCT06209736

Omeros CorporationC3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis

Start: 2024-03-01End: 2026-04-30Target: 20Updated: 2025-07-15

Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

Active, not recruitingNCT06298955

Omeros CorporationParoxysmal Nocturnal Hemoglobinuria

Start: 2024-02-19End: 2027-04-01Target: 25Updated: 2026-07-16